New study tests local injections for stubborn HS lesions

NCT ID NCT07261072

Not yet recruiting Disease control Sponsor: Peking Union Medical College Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares injecting secukinumab directly into skin lesions versus standard under-the-skin injections for people with localized hidradenitis suppurativa (HS). The goal is to see if local delivery works better and causes fewer side effects. Thirty adults with HS lesions in one body area will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab
What this could lead to: If successful, this could offer a more effective and safer way to treat localized HS lesions with secukinumab, reducing side effects.
What could go wrong: This is a small, early exploratory trial with only 30 participants, so results may not apply broadly. Local injections may not work better than standard shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (ACNE INVERSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA (ACNE INVERSA) HIDRADENITIS SUPPURATIVA (HS) SECUKINUMAB

Contacts and locations

Locations

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu 210042

Nanjing, Jiangsu, 210042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.